Terms: = Head and neck cancer AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Treatment
417 results:
1. Enhancing cancer therapy: The role of drug delivery systems in stat3 inhibitor efficacy and safety.
Wang KN; Zhou K; Zhong NN; Cao LM; Li ZZ; Xiao Y; Wang GR; Huo FY; Zhou JJ; Liu B; Bu LL
Life Sci; 2024 Jun; 346():122635. PubMed ID: 38615745
[TBL] [Abstract] [Full Text] [Related]
2. Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
3. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and stat3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H
Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280
[TBL] [Abstract] [Full Text] [Related]
4. Chemerin promotes invasion of oral squamous cell carcinoma by stimulating IL-6 and TNF-α production via stat3 activation.
Lu Z; Liu J; Wan Q; Wu Y; Wu W; Chen Y
Mol Biol Rep; 2024 Mar; 51(1):436. PubMed ID: 38520551
[TBL] [Abstract] [Full Text] [Related]
5. Ascorbic acid induces ferroptosis via stat3/GPX4 signaling in oropharyngeal cancer.
Wu K; Liu L; Wu Z; Huang Q; Zhou L; Xie R; Wang M
Free Radic Res; 2024 Feb; 58(2):117-129. PubMed ID: 38385781
[TBL] [Abstract] [Full Text] [Related]
6. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
7. Cucurbitacin B Inhibits the Malignancy of Esophageal Carcinoma through the KIF20A/JAK/stat3 Signaling Pathway.
Liu C; Ji J; Li C
Am J Chin Med; 2024; 52(1):275-289. PubMed ID: 38291583
[TBL] [Abstract] [Full Text] [Related]
8. AKT2
Chen J; Zhang L; Zhu Y; Zhao D; Zhang J; Zhu Y; Pang J; Xiao Y; Wu Q; Wang Y; Zhan Q
Signal Transduct Target Ther; 2024 Jan; 9(1):21. PubMed ID: 38280862
[TBL] [Abstract] [Full Text] [Related]
9. Exploring the therapeutic potential of curcumin in oral squamous cell carcinoma (HSC-3 cells): Molecular insights into hypoxia-mediated angiogenesis.
Jayaraman S; Veeraraghavan VP; Natarajan SR; Jasmine S
Pathol Res Pract; 2024 Feb; 254():155130. PubMed ID: 38277750
[TBL] [Abstract] [Full Text] [Related]
10. WNT7A promotes tumorigenesis of head and neck squamous cell carcinoma via activating FZD7/JAK1/stat3 signaling.
Huang Q; Xiao Y; Lan T; Lu Y; Huang L; Zheng D
Int J Oral Sci; 2024 Jan; 16(1):7. PubMed ID: 38246919
[TBL] [Abstract] [Full Text] [Related]
11. Targeting IL-6/stat3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC.
Wang Y; Zhou Q; Liu C; Zhang R; Xing B; Du J; Dong L; Zheng J; Chen Z; Sun M; Yao X; Ren Y; Zhou X
Cancer Lett; 2024 Apr; 586():216612. PubMed ID: 38211653
[TBL] [Abstract] [Full Text] [Related]
12. RSK4 promotes the macrophage recruitment and M2 polarization in esophageal squamous cell carcinoma.
He S; Lu M; Zhang L; Wang Z
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):166996. PubMed ID: 38142759
[TBL] [Abstract] [Full Text] [Related]
13. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
[TBL] [Abstract] [Full Text] [Related]
14. Exploring the pharmacological mechanisms of Biyan Qingdu Granula in the treatment after nasopharyngeal carcinoma radiotherapy based on UPLC/Q-TOF MS, network pharmacology and molecular docking.
Yi B; Lv F; Zhang N; Lin J; Xu K; Li C; Li P; Zhao M
J Pharm Biomed Anal; 2024 Feb; 239():115830. PubMed ID: 38096633
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-stat3.
Wu Y; Chen L; Feng C; Wang T; He S; Zheng D; Lin L
BMC Oral Health; 2023 Nov; 23(1):846. PubMed ID: 37946196
[TBL] [Abstract] [Full Text] [Related]
16. Apoptotic activity of genipin in human oral squamous cell carcinoma in vitro by regulating stat3 signaling.
Park DG; Jin B; Lee WW; Kim HJ; Kim JH; Choi SJ; Hong SD; Shin JA; Cho SD
Cell Biochem Funct; 2023 Dec; 41(8):1319-1329. PubMed ID: 37792550
[TBL] [Abstract] [Full Text] [Related]
17. Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/stat3/VEGFA pathway.
Yuan H; Zhao Z; Xu J; Zhang R; Ma L; Han J; Zhao W; Guo M; Song Y
J Exp Clin Cancer Res; 2023 Sep; 42(1):249. PubMed ID: 37752569
[TBL] [Abstract] [Full Text] [Related]
18. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung cancer: The Phase II NeoCOAST Platform Trial.
Cascone T; Kar G; Spicer JD; García-Campelo R; Weder W; Daniel DB; Spigel DR; Hussein M; Mazieres J; Oliveira J; Yau EH; Spira AI; Anagnostou V; Mager R; Hamid O; Cheng LY; Zheng Y; Blando J; Tan TH; Surace M; Rodriguez-Canales J; Gopalakrishnan V; Sellman BR; Grenga I; Soo-Hoo Y; Kumar R; McGrath L; Forde PM
Cancer Discov; 2023 Nov; 13(11):2394-2411. PubMed ID: 37707791
[TBL] [Abstract] [Full Text] [Related]
19. The role of microbiota in esophageal squamous cell carcinoma: A review of the literature.
Chiang HC; Hughes M; Chang WL
Thorac Cancer; 2023 Oct; 14(28):2821-2829. PubMed ID: 37675608
[TBL] [Abstract] [Full Text] [Related]
20. Imipramine Suppresses Tumor Growth and Induces Apoptosis in Oral Squamous Cell Carcinoma: Targeting Multiple Processes and Signaling Pathways.
Hsu LC; Lin CN; Hsu FT; Chen YT; Chang PL; Hsieh LL; Wang HY; Lin KH; Hsiao HC; Tu HF
Anticancer Res; 2023 Sep; 43(9):3987-3996. PubMed ID: 37648317
[TBL] [Abstract] [Full Text] [Related]
[Next]
